Media

Intervacc – Interim report January – September 2025

Vicore Pharma announces successful execution of a directed share issue of approximately USD 48 million (approximately SEK 455 million)

Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update

Ariceum Therapeutics Doses First Patient in SANTANA-225 Phase 1/2 Clinical Trial of 225Ac-SSO110 in Patients with Extensive-Stage Small Cell Lung Cancer or Merkel Cell Carcinoma

Oncopeptides – Annals of Hematology: Expert consensus supports use of Pepaxti in myeloma

Vicore Pharma – Interim Report July – September 2025

Oncopeptides publishes Q3 report 2025

Pretzel Therapeutics Presents Preclinical Data Supporting POLRMT as a Novel Target for the Treatment of Metabolic Disease at ObesityWeek 2025

Research by top universities together with Oncopeptides on NK cell engagers to be presented at ASH

Oncopeptides – Invitation to presentation of the Q3 report 2025